Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis

BACKGROUND: RAS mutations affect prognosis in patients with metastatic colorectal cancer (mCRC) and have been identified as strong negative predictive markers for anti-epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) therapy, but many tumors containing wild-type RAS genes still d...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Xiaona, Li, Yuyao, Li, Yue, Zhang, Xuemei, Shi, Jia, Feng, Hai, Yu, Zhuo, Gao, Yueqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655341/
https://www.ncbi.nlm.nih.gov/pubmed/37974093
http://dx.doi.org/10.1186/s12885-023-11600-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10655341/
https://www.ncbi.nlm.nih.gov/pubmed/37974093
http://dx.doi.org/10.1186/s12885-023-11600-z

Ejemplares similares